Rheumatic Fever

Disclaimer: This information is intended for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Clinicians must always exercise their independent medical judgment in the context of individual patient circumstances. Treatment decisions should be based on current evidence-based guidelines and a thorough assessment of the patient's condition.

Overview

• Definition: Rheumatic Fever (RF) is a delayed, non-suppurative, inflammatory sequela of pharyngitis caused by Group A Streptococcus (GAS), specifically Streptococcus pyogenes. It is an autoimmune condition resulting from molecular mimicry between streptococcal antigens and host tissues, primarily affecting the heart, joints, brain, and skin. Acute Rheumatic Fever (ARF) can lead to Rheumatic Heart Disease (RHD), which is permanent damage to the heart valves.
• Epidemiology:
  • Globally, RF/RHD remains a major public health concern, particularly in low- and middle-income countries (LMICs).
  • Approximately 33 million people are estimated to be living with RHD globally, leading to over 300,000 deaths annually.
  • Incidence rates vary widely: <0.5 per 100,000 in high-income countries (e.g., North America, Western Europe) to >100 per 100,000 in some endemic regions (e.g., Sub-Saharan Africa, Oceania, parts of South Asia).
  • Most commonly affects children and young adults (5-15 years old), but can occur at any age, particularly recurrences.
  • Recurrences are common and increase the risk and severity of RHD.
• Classification:
  • Acute Rheumatic Fever (ARF): The acute inflammatory illness following GAS pharyngitis. It is a diagnosis based on clinical criteria (Modified Jones Criteria).
  • Rheumatic Heart Disease (RHD): The chronic, permanent heart damage (primarily valvular disease) that results from recurrent episodes of ARF. It is the most serious long-term complication.

Pathophysiology

• Mechanism: RF is an autoimmune disease triggered by an antecedent GAS pharyngeal infection (skin infections are generally not associated with RF).
  • Molecular Mimicry: The immune response generated against specific streptococcal antigens (primarily M protein) cross-reacts with host proteins (e.g., myosin in cardiac muscle, vimentin in joint synovial cells, lysoganglioside in basal ganglia neurons, keratin in skin).
  • Antibody-Mediated Damage: Antibodies produced against GAS antigens bind to host tissues, leading to inflammation and tissue damage. For example, anti-streptococcal antibodies that cross-react with cardiac myosin can trigger carditis.
  • T-Cell Mediated Damage: Both CD4+ and CD8+ T cells also play a role in mediating inflammatory damage.
  • Inflammatory Cascade: This cross-reactivity initiates a cascade of inflammation involving cytokines, complement activation, and infiltration of immune cells, leading to characteristic manifestations.
• Risk Factors:
  • Environmental/Socioeconomic: Poverty, overcrowding, poor sanitation, limited access to healthcare, and inadequate access to timely diagnosis and treatment of streptococcal pharyngitis significantly increase risk. These factors facilitate GAS transmission.
  • Host Genetics: Certain HLA Class II alleles (e.g., HLA-DR7) and specific immune response genes are associated with increased susceptibility.
  • Specific GAS Strains: "Rheumatogenic" strains of GAS (certain M serotypes, e.g., M5, M6, M18, M24) are more prone to causing RF.
  • Recurrent Strep Infections: Repeated untreated or inadequately treated GAS pharyngitis significantly increases the risk of initial RF and recurrences.
• Protective Factors:
  • Timely and Appropriate Treatment of Streptococcal Pharyngitis: Rapid diagnosis (e.g., rapid strep antigen test, throat culture) and adequate antibiotic treatment (usually penicillin) within 9 days of symptom onset can prevent the development of ARF.
  • Secondary Prophylaxis: Long-term antibiotic prophylaxis after an ARF episode prevents recurrences and, consequently, the progression to or worsening of RHD.
  • Improved Living Conditions: Addressing socioeconomic disparities, overcrowding, and improving access to healthcare services (including primary prevention programs) reduces GAS transmission and RF incidence.

Clinical Presentation

ARF is a systemic inflammatory disease that typically manifests 2-3 weeks (range 1-5 weeks) after an untreated or inadequately treated GAS pharyngeal infection. The diagnosis of ARF is based on the Modified Jones Criteria (2015 update by AHA), which requires evidence of preceding GAS infection plus: * Two Major Manifestations, OR * One Major and Two Minor Manifestations.

Signs and Symptoms

• Cardinal Features (Major Manifestations of Jones Criteria):
  • Carditis (50-70%): The most serious manifestation. Can affect any layer of the heart (pericarditis, myocarditis, endocarditis). Clinical signs include:
    • New or changing heart murmur (most commonly mitral regurgitation, less often aortic regurgitation).
    • Cardiomegaly on chest X-ray.
    • Pericardial friction rub or effusion.
    • Congestive heart failure (tachycardia disproportionate to fever, dyspnea, orthopnea, crackles, peripheral edema).
    • Echocardiographic findings are crucial for diagnosis (see Diagnostic Approach).
  • Polyarthritis (35-66%): Typically migratory, acute, inflammatory arthritis affecting large joints (knees, ankles, elbows, wrists). Extremely painful, but responds dramatically to salicylates within 24-48 hours. Does not cause permanent joint damage.
  • Sydenham Chorea (St. Vitus' Dance) (10-30%): Neurological manifestation characterized by purposeless, involuntary, rapid movements, muscle weakness, and emotional lability. It is a delayed manifestation, often appearing months after the strep infection, and can be the sole presentation. Worsens with stress, resolves with sleep. More common in females and often self-limiting.
  • Erythema Marginatum (2-10%): A characteristic non-pruritic, transient, serpiginous, macular rash with sharply demarcated borders and central clearing. Typically located on the trunk and proximal extremities, rarely on the face. Exacerbated by heat.
  • Subcutaneous Nodules (<1-10%): Firm, painless, mobile nodules (0.5-2 cm) located over bony prominences (extensor surfaces of wrists, elbows, knees, spine) or tendons. Usually appear weeks into the illness and are associated with severe carditis.
• Minor Manifestations of Jones Criteria:
  • Clinical Findings:
    • Arthralgia (joint pain, without objective signs of inflammation, cannot be counted if polyarthritis is a major criterion).
    • Fever (≥ 38°C or 100.4°F in non-endemic regions; ≥ 38.5°C or 101.3°F in endemic regions, adjusted for age).
  • Laboratory Findings:
    • Elevated acute phase reactants:
      • Erythrocyte Sedimentation Rate (ESR) ≥ 60 mm/hr (or ≥ 30 mm/hr in endemic regions, adjusted for age).
      • C-Reactive Protein (CRP) ≥ 3.0 mg/dL (or ≥ 30 mg/L).
    • Prolonged PR interval on electrocardiogram (EKG) after accounting for age and heart rate (not considered a major criterion for carditis).
• Early Signs: Often non-specific like fever, malaise, fatigue, preceding sore throat (often mild or unnoticed). The onset of migratory arthralgia/arthritis is often the first overt sign.
• Advanced Signs: Manifestations of chronic RHD, such as progressive valvular heart disease leading to heart failure (dyspnea, orthopnea, peripheral edema), pulmonary hypertension, atrial fibrillation, and systemic embolization.
• Atypical Presentations:
  • Isolated Chorea: Sydenham chorea can occur months after the GAS infection and without any other signs of ARF. In such cases, it is considered sufficient for diagnosis with evidence of preceding GAS.
  • Indolent Carditis: In endemic areas, carditis can develop without other typical acute manifestations, often detected during screening echocardiography.
  • Adults: RF can present with more subtle or atypical features in adults, where RHD is usually a result of childhood disease.

Physical Examination

• General Appearance: Febrile, ill-appearing, restless if chorea present.
• Inspection:
  • Skin: Erythema marginatum (check trunk, proximal limbs, look for evanescent nature).
  • Joints: Swelling, redness, warmth, tenderness of large joints (migratory pattern).
  • Neurological: Observe for choreiform movements (involuntary, jerky, purposeless movements, "milkmaid's grip," "pronator drift") and emotional lability (Sydenham chorea).
  • Heart: Inspect for signs of heart failure (jugular venous distension, peripheral edema).
• Palpation:
  • Joints: Tenderness, warmth, effusions.
  • Subcutaneous Nodules: Palpate over bony prominences (elbows, knees, spine, Achilles tendon).
  • Precordium: Palpate for thrills (systolic or diastolic) indicative of severe murmurs, or heaves (ventricular hypertrophy).
• Auscultation:
  • Cardiac: Crucial for carditis. Listen for:
    • Mitral Regurgitation: Apical holosystolic murmur radiating to the axilla. Often the earliest and most common valvular lesion.
    • Aortic Regurgitation: Early diastolic murmur heard best at the left sternal border with the patient leaning forward and exhaling.
    • Pericardial Rub: A coarse, scratchy sound if pericarditis is present.
    • Signs of heart failure: Tachycardia, S3 gallop.
  • Pulmonary: Auscultate for crackles or rales, indicative of pulmonary congestion in heart failure.
• Special Tests: Not specific physical exam maneuvers, but emphasize thoroughness in looking for all Jones Criteria manifestations.

Diagnostic Approach

The diagnosis of ARF is a clinical one, based on the Modified Jones Criteria after confirming evidence of a preceding GAS infection.

History Taking

• Key Questions:
  • Antecedent Infection: History of sore throat (pharyngitis) 1-5 weeks prior? Even mild or asymptomatic infections can precede RF. Ask about other family members with strep throat.
  • Joint Symptoms: History of joint pain, swelling, redness, warmth? Is it migratory? How quickly did it resolve with pain relievers?
  • Cardiac Symptoms: Shortness of breath, fatigue, chest pain, palpitations, orthopnea, paroxysmal nocturnal dyspnea?
  • Neurological Symptoms: Involuntary movements, clumsiness, emotional changes, difficulty writing or performing fine motor tasks? (For chorea, onset can be delayed by months).
  • Skin Manifestations: Any rash, particularly on the trunk or limbs that appears transiently or with heat? Any lumps under the skin?
  • General Symptoms: Fever, fatigue, weight loss, abdominal pain.
  • Past Medical History: Previous episodes of RF, or diagnosis of RHD? Family history of RF/RHD.
  • Geographic and Socioeconomic Context: Living in an endemic area or crowded conditions? Access to healthcare.
• Red Flags:
  • New heart murmur or changes in a pre-existing murmur.
  • Signs of congestive heart failure (e.g., severe dyspnea, orthopnea).
  • Unexplained involuntary movements (chorea).
  • Severe, migratory polyarthritis.

Laboratory Tests

• First-Line:
  • Evidence of Preceding GAS Infection: Crucial for diagnosis, as none of the manifestations are pathognomonic.
    • Antistreptolysin O (ASO) Titer: Most commonly used. Peaks 3-6 weeks after infection, remains elevated for months. A rise in titer on paired sera (taken 1-2 weeks apart) is highly suggestive. A single high titer above the upper limit of normal for age/location is also indicative.
    • Anti-DNase B Titer: More sensitive than ASO for documenting prior GAS skin infections (impetigo), but also elevated after pharyngitis. Useful if ASO is negative or equivocal.
    • Other streptococcal antibody tests (e.g., anti-hyaluronidase) can also be used.
    • Throat Culture/Rapid Antigen Detection Test (RADT): A positive result indicates current GAS infection, but in ARF, the active infection has usually resolved, so these are often negative (positive in only 25% of ARF cases). A positive result is sufficient evidence of preceding infection if recent pharyngitis history.
  • Acute Phase Reactants:
    • C-Reactive Protein (CRP): Elevated (>3.0 mg/dL or >30 mg/L) during acute inflammation. Normalizes faster than ESR.
    • Erythrocyte Sedimentation Rate (ESR): Elevated (>60 mm/hr, or >30 mm/hr in endemic areas) during acute inflammation. Remains elevated longer than CRP.
  • Complete Blood Count (CBC): May show leukocytosis (elevated white blood cell count) and mild anemia (anemia of chronic disease).
• Confirmatory: No single laboratory test confirms ARF. Diagnosis relies on combining clinical manifestations (Jones Criteria) with laboratory evidence of recent GAS infection.
• Monitoring:
  • CRP/ESR: To monitor the resolution of the inflammatory process and response to anti-inflammatory therapy. Normalization indicates resolution of acute inflammation.
  • Serial Echocardiography: To monitor for progression or resolution of carditis, or development/worsening of RHD.

Imaging

• Recommended:
  • Echocardiography (ECHO) with Doppler:
    • Essential for diagnosis of carditis: Gold standard to detect valvular inflammation and dysfunction, even in the absence of a murmur (subclinical carditis).
    • Indications for Carditis:
      • Mitral regurgitation: Pathological jet (length > 2 cm in at least one view, peak velocity > 3 m/s, pan-systolic jet in at least two views).
      • Aortic regurgitation: Pathological jet (length > 1 cm, peak velocity > 3 m/s, pan-diastolic jet in at least two views).
      • Valve morphological changes: Annular dilatation, chordal thickening, leaflet thickening/restricted motion.
      • Pericardial effusion.
    • Diagnosis of RHD: Identifies chronic valvular damage (e.g., mitral stenosis, aortic stenosis, mixed lesions).
  • Chest X-ray (CXR): May show cardiomegaly, pulmonary congestion, or pleural effusions in cases of severe carditis with heart failure.
• Advanced:
  • Cardiac MRI: Rarely needed for ARF diagnosis. Can provide detailed assessment of myocardial inflammation, valve morphology, and function, but typically reserved for complex RHD cases or when ECHO is inconclusive.
  • Brain MRI/CT: Not typically used for chorea diagnosis unless considering other neurological conditions, as chorea is a clinical diagnosis.

Management

Management of ARF focuses on treating the acute inflammatory process, eradicating the GAS infection, managing symptoms, preventing recurrences, and treating long-term complications (RHD).

Acute Management

• Immediate (First 24 hours):
  • Hospitalization: Recommended for all patients with suspected ARF, especially those with carditis, for close monitoring and initiation of therapy.
  • Diagnosis Confirmation: Perform full diagnostic workup (blood tests, EKG, ECHO).
  • Eradication of GAS: Administer antibiotics to eliminate any residual GAS and prevent further antigen stimulation.
    • Benzathine Penicillin G (BPG): Single intramuscular injection is the preferred treatment.
      • Children weighing <27 kg: 600,000 units IM
      • Children weighing ≥27 kg and adults: 1,200,000 units IM
    • Oral penicillin V (e.g., 250 mg 2-3 times daily for 10 days for children, 500 mg 2-3 times daily for 10 days for adults) or Amoxicillin can be used if IM BPG is not feasible, but adherence is critical.
    • For penicillin-allergic patients: Macrolides (e.g., Azithromycin 12 mg/kg/day once daily for 5 days, max 500 mg; or Clarithromycin 7.5 mg/kg twice daily for 10 days, max 250 mg twice daily; or Erythromycin 20-50 mg/kg/day in 2-4 divided doses for 10 days, max 1g/day).
• Stabilization (Early Management Priorities):
  • Anti-inflammatory Therapy:
    • Arthritis: Aspirin is the drug of choice. Provides rapid and dramatic relief (within 24-48 hours).
      • Dosage: 80-100 mg/kg/day in 4-5 divided doses (max 8 g/day) until symptoms resolve (1-2 weeks), then taper over 2-3 weeks. Monitor for salicylism.
    • Carditis (Mild/No Carditis): Aspirin may be sufficient if no evidence of heart failure or significant valvulitis.
    • Carditis (Moderate to Severe): Corticosteroids are indicated for patients with moderate to severe carditis (cardiomegaly, heart failure, significant valvulitis).
      • Prednisone: 1-2 mg/kg/day (max 80 mg/day) in divided doses. Continue for 2-6 weeks (or until CRP/ESR normalize), then taper slowly over 2-3 weeks. Relapse of inflammation during tapering may require re-escalation.
    • Chorea: Sedation and chorea-specific medications.
      • Mild cases: May resolve spontaneously or with reassurance and quiet environment.
      • Severe cases: Haloperidol (0.01-0.03 mg/kg/day in 2-3 doses, max 10 mg/day), Valproic acid (15-30 mg/kg/day), Carbamazepine. Benzodiazepines (e.g., diazepam) for severe agitation.
  • Supportive Care: Bed rest during the acute inflammatory phase, particularly for patients with carditis, until CRP/ESR normalize and symptoms subside.
• Emergency (Crisis Management):
  • Heart Failure: Manage with diuretics (e.g., Furosemide), ACE inhibitors (e.g., Captopril, Enalapril), and possibly digoxin. Inotropes for severe cases. Oxygen therapy.
  • Pericardial Effusion with Tamponade: Pericardiocentesis.

Chronic Management

• Pharmacological:
  • Secondary Prophylaxis (Crucial for preventing recurrences): Long-term regular antibiotic administration to prevent recurrent GAS infections and subsequent ARF episodes.
    • Drug of Choice: Benzathine Penicillin G (BPG) IM injection.
      • Children weighing <27 kg: 600,000 units every 3-4 weeks.
      • Children weighing ≥27 kg and adults: 1,200,000 units every 3-4 weeks.
      • Some guidelines suggest 3-week intervals for high-risk patients.
    • Oral Alternatives (if IM is not feasible/tolerated, but less reliable):
      • Penicillin V: 250 mg twice daily.
      • Sulfadiazine: 0.5 g once daily (for <27 kg) or 1.0 g once daily (for ≥27 kg).
      • Macrolides (for penicillin-allergic patients): Erythromycin 250 mg twice daily.
    • Duration of Secondary Prophylaxis:
      • ARF without carditis: 5 years after the last episode or until 21 years of age, whichever is longer.
      • ARF with carditis but no residual RHD: 10 years after the last episode or until 21 years of age, whichever is longer.
      • ARF with carditis and persistent RHD (valvular disease): At least 10 years after the last episode or until 40 years of age, potentially lifelong prophylaxis. Lifelong prophylaxis is generally recommended for patients with established RHD, especially if they are at high risk of exposure to GAS or have had valve surgery.
  • Management of RHD Complications:
    • Heart Failure: Diuretics, ACE inhibitors, beta-blockers.
    • Arrhythmias: Beta-blockers, antiarrhythmic drugs, anticoagulation (for atrial fibrillation, especially if mechanical valve or high stroke risk).
    • Infective Endocarditis Prophylaxis: Not routinely recommended for RHD patients unless they have prosthetic valves or a history of endocarditis. Refer to current endocarditis prophylaxis guidelines.
    • Surgical Intervention: Valve repair or replacement for severe RHD (e.g., severe mitral stenosis, severe aortic regurgitation) when medical management fails or symptoms progress.
• Non-pharmacological:
  • Rest: During the acute phase, especially with carditis, until inflammatory markers normalize. Gradual return to activity.
  • Education: Patient and family education on the disease, importance of prophylaxis, and signs of recurrence.
  • Nutritional Support: Ensure adequate nutrition.
• Monitoring:
  • Regular clinical follow-up, physical examination (cardiac auscultation).
  • Serial echocardiograms: Annually or biannually for RHD patients, or more frequently if symptoms change or during childhood to monitor valve progression.
  • Monitoring for complications of RHD (heart failure, arrhythmias, infective endocarditis).
  • Adherence checks for secondary prophylaxis.

Treatment Algorithms

• First-Line:
  1. Confirm Diagnosis: Modified Jones Criteria + Evidence of recent GAS infection.
  2. Eradicate GAS: Single dose Benzathine Penicillin G IM.
  3. Manage Inflammation:
     • Polyarthritis/Mild Carditis: High-dose Aspirin.
     • Moderate/Severe Carditis (with cardiomegaly, CHF): Oral Prednisone.
     • Chorea: Haloperidol or Valproate if severe.
  4. Initiate Secondary Prophylaxis: BPG IM every 3-4 weeks.
  5. Supportive Care: Bed rest, symptomatic treatment for CHF if present.
• Second-Line:
  • If Aspirin is contraindicated or ineffective for arthritis: NSAIDs (e.g., Naproxen) may be used, but generally less effective for RF arthritis.
  • If corticosteroids are contraindicated or insufficient for carditis: Consider IVIG, immunosuppressants (e.g., azathioprine, cyclosporine, rarely methotrexate) in refractory, severe cases, but this is rare and usually only in consultation with a cardiologist/rheumatologist.
  • For refractory chorea: Consider IVIG, plasma exchange in very severe, debilitating cases, but largely experimental.
• Refractory Cases:
  • Persistent Carditis: Re-evaluate corticosteroid dosage and duration, rule out other causes of inflammation. May require prolonged steroid courses or, rarely, adjunctive immunosuppressants.
  • Progressive RHD: Surgical evaluation for valve repair or replacement if severe valvular disease causes significant symptoms or ventricular dysfunction despite optimal medical management.
  • Non-adherence to prophylaxis: Address barriers to adherence, consider directly observed therapy, patient education.

Complications

• Common:
  • Chronic Rheumatic Heart Disease (RHD): Permanent damage to heart valves, most commonly mitral valve (stenosis, regurgitation, or mixed), followed by aortic valve (regurgitation, stenosis, or mixed). Tricuspid and pulmonary valves are less commonly affected.
  • Valvular Heart Disease: Manifests as murmurs, leading to symptoms like dyspnea, fatigue, chest pain, and syncope over time.
  • Recurrent ARF Episodes: Each recurrence further damages the heart valves, worsening RHD.
• Serious:
  • Congestive Heart Failure: Due to severe valvular dysfunction (e.g., severe mitral regurgitation, severe mitral stenosis leading to pulmonary hypertension, left ventricular dysfunction).
  • Infective Endocarditis: Damaged rheumatic valves are predisposed to bacterial colonization and infection, a life-threatening complication.
  • Atrial Fibrillation: Common arrhythmia in advanced RHD, especially with mitral stenosis, due to left atrial enlargement. Increases risk of thromboembolic stroke.
  • Stroke/Systemic Embolism: Due to atrial fibrillation (thrombi forming in the left atrium) or rarely, from vegetations in infective endocarditis.
  • Pulmonary Hypertension: A common consequence of severe mitral valve disease.
• Long-term:
  • Need for Cardiac Surgery: Valve repair or replacement.
  • Chronic Disability: Due to heart failure, limitations from chorea, or post-stroke sequelae.
  • Premature Mortality: From severe RHD and its complications.

Prognosis

• Factors:
  • Severity of Initial Carditis: The presence and severity of carditis during the initial ARF episode are the most important prognostic factors. Severe carditis is a strong predictor of progressive RHD.
  • Recurrences: Each recurrence of ARF significantly worsens the prognosis, accelerating the development and progression of RHD.
  • Adherence to Secondary Prophylaxis: Strict adherence dramatically improves prognosis by preventing recurrences.
  • Access to Healthcare: Timely diagnosis, appropriate acute management, and long-term follow-up are crucial.
  • Socioeconomic Status: Poorer outcomes are often linked to lower socioeconomic status, due to increased exposure risk and limited access to care.
• Survival:
  • Acute mortality from ARF is low, usually related to severe heart failure.
  • Long-term mortality is primarily due to complications of RHD (heart failure, stroke, infective endocarditis).
  • With good secondary prophylaxis and access to surgical care, the prognosis has improved, but RHD still causes significant morbidity and premature mortality, particularly in LMICs.
• Quality of Life: Can be significantly impaired by chronic RHD, requiring lifelong medication, frequent medical visits, and potentially multiple cardiac surgeries. Sydenham chorea, though usually self-limiting, can cause significant distress and temporary functional impairment.

Prevention

• Primary Prevention: Aims to prevent the initial episode of ARF by treating GAS pharyngitis effectively.
  • Early Diagnosis of GAS Pharyngitis: Throat swab culture or rapid antigen detection tests (RADT) are essential for confirming GAS infection in symptomatic individuals (sore throat, fever, exudative tonsillitis, swollen tender anterior cervical lymph nodes). Clinical diagnosis alone is unreliable.
  • Adequate Antibiotic Treatment: Administer appropriate antibiotics within 9 days of symptom onset.
    • Drug of Choice: Penicillin.
      • Benzathine Penicillin G: Single IM injection (600,000 units for children <27 kg; 1,200,000 units for children ≥27 kg and adults). Preferred due to assured compliance.
      • Penicillin V: Oral, 250 mg 2-3 times daily for 10 days (children) or 500 mg 2-3 times daily for 10 days (adults).
      • Amoxicillin: Oral, 50 mg/kg once daily (max 1000 mg) or 25 mg/kg twice daily (max 500 mg twice daily) for 10 days.
    • For Penicillin Allergic Patients:
      • Cephalexin: 25-50 mg/kg/day in 2-4 doses (max 1 g/day) for 10 days.
      • Clindamycin: 7 mg/kg/dose 3 times daily (max 300 mg/dose) for 10 days.
      • Azithromycin: 12 mg/kg once daily (max 500 mg/day) for 5 days.
  • Public Health Measures: Improved living conditions, hygiene, and access to healthcare.
• Secondary Prevention: Aims to prevent recurrent episodes of ARF in individuals who have had a confirmed episode. This is the cornerstone of RHD prevention.
  • Continuous Antibiotic Prophylaxis: Lifelong or extended periods of regular antibiotic administration (see Chronic Management - Secondary Prophylaxis for dosages and durations).
  • Patient Education: Emphasizing the critical importance of adherence to prophylaxis.
  • Registries and Recall Systems: In endemic areas, establishing registries to track RF patients and recall systems for scheduled BPG injections helps improve adherence.
• Tertiary Prevention: Focuses on managing existing RHD to prevent progression of valve damage and complications.
  • Regular Clinical Monitoring: Including echocardiography.
  • Medical Management of RHD Complications: Heart failure, arrhythmias, infective endocarditis prophylaxis (when indicated).
  • Surgical Intervention: Valve repair or replacement when medically necessary.

Special Populations

• Pediatric:
  • ARF is predominantly a disease of childhood (5-15 years).
  • Diagnosis and initiation of secondary prophylaxis are critical in this age group to prevent lifelong RHD.
  • Sydenham chorea is more common in children and adolescents.
  • Compliance with long-term prophylaxis can be challenging and requires family education and support.
• Geriatric:
  • New onset ARF is rare in the elderly.
  • Elderly patients with RHD often present with complications like heart failure, atrial fibrillation, and stroke.
  • Management of RHD in the elderly must consider comorbidities, polypharmacy, and potential frailty for surgical interventions.
• Pregnancy:
  • Women with pre-existing RHD require careful monitoring during pregnancy due to increased hemodynamic burden, which can exacerbate valvular lesions and precipitate heart failure.
  • Increased risk of arrhythmias (especially atrial fibrillation) and thromboembolism.
  • Anticoagulation for mechanical heart valves or atrial fibrillation needs careful management to balance maternal and fetal risks. Warfarin is teratogenic in the first trimester; heparin (unfractionated or low molecular weight) may be used.
  • Secondary prophylaxis should be continued throughout pregnancy and postpartum.
• Comorbidities:
  • Diabetes, Hypertension, CKD: These conditions can complicate RHD management, particularly heart failure. Careful medication selection (e.g., ACE inhibitors for heart failure benefit but require renal function monitoring).
  • Infective Endocarditis: Patients with RHD, especially those with prosthetic valves or a history of endocarditis, are at higher risk and require meticulous dental hygiene and appropriate endocarditis prophylaxis for certain procedures.

Clinical Pearls

• Diagnostic:
  • "Rheumatic fever licks the joints but bites the heart." This adage highlights the transient nature of arthritis and the permanent potential damage to the heart.
  • Always search for evidence of preceding GAS infection. Without it, the diagnosis of ARF is highly unlikely (except for recurrent ARF in those with established RHD or isolated chorea in a high-risk setting).
  • Echocardiography is mandatory for all suspected ARF cases, even in the absence of a murmur, to detect subclinical carditis.
  • Chorea can be a very delayed manifestation (up to 6 months post-infection) and may occur in isolation.
  • Arthralgia alone (without objective inflammation) counts as a minor criterion. If there's true arthritis, it's a major criterion.
• Treatment:
  • Antibiotics for GAS eradication are not for symptomatic relief of ARF symptoms. They prevent further antigen stimulation and are crucial for primary and secondary prevention.
  • Aspirin provides dramatic relief for rheumatic arthritis. Lack of response to high-dose aspirin for arthritis should prompt reconsideration of the diagnosis.
  • Corticosteroids are reserved for moderate-to-severe carditis. They reduce inflammation and may prevent progression of heart damage.
  • Secondary prophylaxis is the single most important intervention for long-term prognosis. Adherence is paramount.
• Pitfalls:
  • Misdiagnosing other arthritides as RF: Always differentiate from septic arthritis, juvenile idiopathic arthritis, or post-streptococcal reactive arthritis (PReS, which does not progress to RHD). PReS generally has a shorter latency and less dramatic response to salicylates.
  • Missing subtle carditis: Relying solely on auscultation can miss significant valvulitis detectable only by ECHO.
  • Inadequate duration of secondary prophylaxis: Leading to preventable recurrences and progressive RHD.
  • Treating an existing GAS pharyngitis with antibiotics as the sole management for ARF symptoms: This is insufficient for the inflammatory process of ARF.
  • Not differentiating between ARF and PReS: PReS does not require secondary prophylaxis, while ARF does.

Recent Updates

• Guidelines: The 2015 American Heart Association (AHA) and 2018 World Health Organization (WHO) guidelines provide updated recommendations for diagnosis (Modified Jones Criteria), management, and secondary prophylaxis. The 2015 AHA guidelines simplified some aspects for clarity (e.g., specific fever thresholds, ESR/CRP cutoffs for endemic/non-endemic settings).
• Evidence:
  • Growing evidence supports the role of "subclinical carditis" detected by echocardiography as a marker for ARF, even in the absence of a murmur. Screening programs using handheld echocardiography are being implemented in endemic areas to detect early RHD.
  • Ongoing research into the precise immunopathogenesis of RF and RHD aims to identify novel therapeutic targets and develop a vaccine against GAS.
  • Emphasis on improving adherence to secondary prophylaxis, including exploring longer-acting penicillin formulations or alternative delivery methods.
• Controversies:
  • Optimal duration of secondary prophylaxis: While general guidelines exist, the optimal stopping age for certain RHD severity levels remains debated, especially in high-endemicity settings.
  • Role of imaging-based screening for RHD: While effective for detection, questions remain about cost-effectiveness and appropriate follow-up/management strategies for subclinical cases in resource-limited settings.
  • Feasibility and impact of a GAS vaccine: Significant progress has been made, but challenges remain in developing a broadly protective and safe vaccine, crucial for true primary prevention.

Key References

• Guidelines:
  • Gewitz, M. H., et al. (2015). "Revision of the Jones Criteria for the Diagnosis of Acute Rheumatic Fever in the Era of Doppler Echocardiography: A Scientific Statement From the American Heart Association." Circulation, 131(20), 1806-1818.
  • World Health Organization. (2018). Rheumatic fever and rheumatic heart disease: report of a WHO expert consultation. WHO Press.
  • Australian Guidelines for the Prevention, Diagnosis and Management of Acute Rheumatic Fever and Rheumatic Heart Disease (3rd Edition, 2020).
• Studies:
  • Marijon, E., et al. (2007). "Prevalence of rheumatic heart disease detected by echocardiographic screening." The New England Journal of Medicine, 357(5), 470-476. (Landmark study on echocardiographic screening).
  • Watkins, D. A., et al. (2017). "Global, Regional, and National Burden of Rheumatic Heart Disease, 1990-2015." The New England Journal of Medicine, 377(8), 713-722. (Key epidemiological data).
• Reviews:
  • Carapetis, J. R., et al. (2016). "Acute rheumatic fever and rheumatic heart disease." The Lancet, 387(10025), 1816-1828.
  • Robertson, K. A., et al. (2018). "Diagnosis and treatment of acute rheumatic fever." Journal of the American College of Cardiology, 71(15), 1639-1650.